TR201902517T4 - 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi. - Google Patents

25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi. Download PDF

Info

Publication number
TR201902517T4
TR201902517T4 TR2019/02517T TR201902517T TR201902517T4 TR 201902517 T4 TR201902517 T4 TR 201902517T4 TR 2019/02517 T TR2019/02517 T TR 2019/02517T TR 201902517 T TR201902517 T TR 201902517T TR 201902517 T4 TR201902517 T4 TR 201902517T4
Authority
TR
Turkey
Prior art keywords
hydroxyvitamin
conditions associated
treatment
eotaxin
increased eotaxin
Prior art date
Application number
TR2019/02517T
Other languages
English (en)
Inventor
Krammer-Lukas Stephanie
Stoecklin Elisabeth
Schwager Joseph
Wolfram Swen
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of TR201902517T4 publication Critical patent/TR201902517T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

Mevcut buluş, 25-hidroksivitamin D3 (kalsifediol) ile bir insanda artan bir eotaksin düzeyi ile ilişkilendirilen durumları tedavi etme/önleme ile ilgilidir. İsteğe bağlı olarak vitamin D3, 25-hidroksivitamin D3 ile birlikte kullanılabilir.
TR2019/02517T 2010-12-06 2011-12-05 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi. TR201902517T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10193847 2010-12-06

Publications (1)

Publication Number Publication Date
TR201902517T4 true TR201902517T4 (tr) 2019-03-21

Family

ID=43585621

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02517T TR201902517T4 (tr) 2010-12-06 2011-12-05 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi.

Country Status (10)

Country Link
US (2) US20130252927A1 (tr)
EP (1) EP2648737B1 (tr)
JP (1) JP5982695B2 (tr)
KR (1) KR101895764B1 (tr)
CN (2) CN106924268A (tr)
BR (1) BR112013011259B1 (tr)
ES (1) ES2712740T3 (tr)
PL (1) PL2648737T3 (tr)
TR (1) TR201902517T4 (tr)
WO (1) WO2012076429A1 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029572T2 (en) 2006-02-03 2017-03-28 Opko Renal Llc Treatment of Vitamin D Insufficiency and Deficiency with 25-Hydroxy-D2 and 25-Hydroxy-D3
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
EP3542792B1 (en) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Controlled release 25-hydroxyvitamin d
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101852042B1 (ko) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN114681468A (zh) 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d的辅助疗法
TW202214257A (zh) 2016-03-28 2022-04-16 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素d治療之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216178A (ja) * 1982-06-11 1983-12-15 Chugai Pharmaceut Co Ltd ５，６−エポキシ化ビタミンｄ↓３誘導体
CA2005227A1 (en) 1988-12-14 1990-06-14 Choju Aoki Pharmaceutical preparation for chronic hepatitis treatment
US5043170A (en) 1989-02-14 1991-08-27 Hoffmann-La Roche Inc. Animal feed composition containing a vitamin D metabolite
US5695794A (en) 1995-08-10 1997-12-09 Amoco Corporation Use of 25-hydroxycholecalciferol in a dietary supplement process for ameliorating the effects of tibial dyschondroplasia in poultry while maintaining weight gain
JPH1087495A (ja) * 1996-09-17 1998-04-07 Teijin Ltd 活性型ビタミンｄ含有予防剤あるいは治療剤
AU4919597A (en) 1996-10-31 1998-05-22 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
JP2000191537A (ja) 1998-12-24 2000-07-11 Teijin Ltd 炎症性呼吸器疾患治療剤
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
PL1516540T3 (pl) 2003-09-22 2013-02-28 Dsm Ip Assets Bv Zastosowanie związków z grupy witaminy D
EP1962614B1 (en) 2005-11-25 2010-08-04 DSM IP Assets B.V. Use of 25-hydroxy vitamin d3 to improve vitality of animals
US20080038410A1 (en) 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
WO2008134523A1 (en) * 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101495578B1 (ko) * 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
US20110052707A1 (en) * 2008-02-12 2011-03-03 Neil Robert Buck Combination of vitamin d and 25-hydroxyvitamin d 3
WO2009101132A1 (en) * 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Combination of vitamin d and 25-hydroxyvitamin d 3

Also Published As

Publication number Publication date
CN106924268A (zh) 2017-07-07
KR101895764B1 (ko) 2018-09-07
PL2648737T3 (pl) 2019-05-31
BR112013011259A2 (pt) 2016-11-01
BR112013011259B1 (pt) 2020-03-03
JP5982695B2 (ja) 2016-08-31
JP2013545766A (ja) 2013-12-26
US20130252927A1 (en) 2013-09-26
US20170106005A1 (en) 2017-04-20
CN103237552A (zh) 2013-08-07
US10357501B2 (en) 2019-07-23
EP2648737B1 (en) 2018-11-21
ES2712740T3 (es) 2019-05-14
CN103237552B (zh) 2018-03-06
KR20130135868A (ko) 2013-12-11
EP2648737A1 (en) 2013-10-16
WO2012076429A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
TR201902517T4 (tr) 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi.
SG10201806787VA (en) Modulators of complement factor b
IN2015DN00895A (tr)
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
DK2858496T3 (da) Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
CL2012003385A1 (es) Tratamiento para la incontinencia.
SG10201809953QA (en) Compositions and methods for modulating complement factor b expression
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
MX2012000006A (es) L-serina para usarse como un farmaco para prevenir y/o tratar una respuesta inflamatoria de la piel.
AR093632A1 (es) Tratamiento de cafe soluble
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
TR201900665T4 (tr) Diyabetik nefropatinin tedavi yöntemi.
CL2016001428A1 (es) Uso de una composicion con ejercicios cognitivos util para la prevencion o el tratamiento de un desarrollo cognitivo retrasado en los niños.
TW201612313A (en) Uses of ligustilide
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
AU346001S (en) Animal waste and organic matter digester
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
PH12017500084A1 (en) Vitamin b2 and its use
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
IN2014KN01772A (tr)
PH12016500541A1 (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
TW201612314A (en) Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases
TR201306238A2 (tr) Dikkat ve konsantrasyon bozukluklarının tedavisine yönelik bir kompozisyon.